Glenmark Pharmaceuticals Ltd stock is about 9% below its 52-week high of ₹2,297.90 seen on 11 March, amid better business recovery. Consolidated revenue in the December quarter (Q3FY26) increased 15% year-on-year to ₹3,901 crore, while Ebitda margin expanded to 22% from 18%, reflecting better operating efficiency and product mix.
A fresh trigger is the launch of Glipiq (semaglutide) on 21 March, marking its entry into the fast-growing weight loss market. Glenmark appears well-positioned to benefit, primarily due to its pricing.
While global GLP-1 therapies cost ₹15,000–30,000 per month, Glenmark’s semaglutide is priced at ₹1,300–1,800 per month. This sharp drop improves accessibility, thus boosting volumes.
Glenmark’s core business offers support. India and North America grew 22% and 24%, respectively, in Q3FY26, highlighting strong execution. The India business is outperforming the market in core therapies like respiratory, dermatology, and cardiac, aided by brand strength and new product launches.
In North America, Glenmark is building a pipeline of complex generics, injectables, and respiratory products, which typically offer better margins versus commoditized generics.
Glenmark currently has over 50 ANDA (abbreviated new drug application) filings pending, providing visibility for future launches. Plus, restarting the Monroe manufacturing facility after the USFDA clearance helps scale complex products’ output over time.
Scaling global brands is another growth lever. Products like Ryaltris are already commercialized in over 50 markets. The company is also expanding its presence in branded markets across Europe and emerging markets, where pricing pressure is lower compared to the US.
Meanwhile, the management has highlighted 7–8 innovative and specialty assets that are expected to be launched over the next few years, particularly in oncology, dermatology, and respiratory segments.
Glenmark’s margin may get a further lift as the share of specialty products increases, global brands scale, and the US portfolio shifts towards complex generics. Better utilization of manufacturing facilities, especially in the US, can also aid margin expansion.
The GLP-1 segment, including semaglutide, fits well into this broader strategy. It adds a chronic, high-volume category where the company can leverage its cost advantage and existing capabilities, though the near-term earnings impact is limited.
Glenmark’s shares trade at around 22x FY28 estimated earnings. Valuations don’t appear demanding. “Enhanced free cash generation and maintaining a prudent balance sheet are essential avenues to be watched out in quarters ahead,” said ICICI Securities in its Q3FY26 review report.